Peripear
Developing a hands-free, wearable warmth-delivery device to reduce perineal tearing during childbirth.
Website: https://peri-pear.com
PUBLIC
| Attribute | Details |
|---|---|
| Name | Peripear |
| Tagline | Developing a hands-free, wearable warmth-delivery device to reduce perineal tearing during childbirth. |
| Headquarters | Oxford, United Kingdom |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Hardware |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder (Dr Verity Biggs) |
| Funding Label | Pre-seed |
| Total Disclosed | $1.5M USD (approx. £1.2M) [Playfair Capital] |
Links
PUBLIC
- Website: https://peri-pear.com
Data Accuracy: GREEN -- Confirmed by company website and multiple source citations.
Executive Summary
PUBLIC
Peripear is developing a hands-free, wearable device designed to reduce perineal tearing during childbirth, a common yet under-addressed complication with significant clinical and economic consequences [Perplexity Sonar Pro Brief]. The company's wedge is to standardize the evidence-based warm compress intervention, which studies suggest can reduce severe tears by up to 50%, into a scalable, automated device that does not add to the workload of already stretched midwifery staff [Angel Investment Network, 2024]. Founder Dr. Verity Biggs, an NHS GP and menopause specialist, initiated the project, teaming up with a collaborator named Evi to translate clinical need into a tangible product [peri-pear.com]. The company recently secured a £1.2 million pre-seed round (approximately $1.5 million) led by Playfair Capital, with participation from Zinc VC, SyndicateRoom, and Hermesa, indicating strong early-stage venture backing for its hardware-based, B2B model targeting hospital labor and delivery units [Playfair Capital]. Over the next 12 to 18 months, the key milestones to watch are the progression from a single-use, heat-applying prototype to a regulated medical device, the initiation of clinical trials or pilot deployments within the NHS, and the execution of the roadmap toward a reusable version intended for use from late pregnancy through postpartum [PreSeed Now, June 2024].
Data Accuracy: GREEN -- Core product claims and funding details corroborated by multiple independent sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Hardware |
| Geography | Western Europe (United Kingdom) |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Pre-seed |
Company Overview
PUBLIC
Peripear Ltd was incorporated in Oxford, United Kingdom, on 16 January 2024, with its registered office at 105 Godstow Road, Wolvercote, Oxford [GOV.UK, 2024]. The company was founded by Dr. Verity Biggs, a practicing NHS GP and menopause specialist, who has described the venture as her mission to transform childbirth experiences [Angel Investment Network, 2024]. The founding narrative centers on packaging a clinically proven but labor-intensive intervention, manual warm compresses, into a standardized, hands-free device to address perineal tearing, a common yet often overlooked source of maternal trauma.
Key milestones to date are concentrated in its first year. The company began closing an initial pre-seed round in 2024, securing commitments of £800,000 from investors including Zinc VC, SyndicateRoom, and Hermesa [Angel Investment Network, 2024]. This was followed by a larger, £1.2 million (approximately $1.5 million USD) pre-seed round in 2025, which was led by London-based venture firm Playfair Capital [Playfair Capital], [Kruze Consulting, 2025]. The company remains pre-market, with its primary public milestones being its incorporation, its initial and follow-on pre-seed fundraises, and its selection for profiles by NHS-aligned innovation bodies [Health Innovation Network, 2024].
Data Accuracy: GREEN -- Confirmed by Companies House filings, investor announcements, and multiple independent media reports.
Product and Technology
MIXED
Peripear’s product is a hardware intervention designed to automate a clinical best practice. The company is developing a single-use, wearable device that adheres to the perineum during the second stage of labor, delivering controlled warmth and moisture [Perplexity Sonar Pro Brief]. The core proposition is to standardize the “warm compress” technique, which clinical studies suggest can reduce severe perineal tearing by up to 50% [Perplexity Sonar Pro Brief]. The device is designed to be hands-free, requiring no additional clinician involvement once placed, and maintains a temperature of at least 38°C throughout crowning [Perplexity Sonar Pro Brief]. This aims to address a critical gap in maternal care by making an evidence-based but labor-intensive intervention scalable and consistent.
The current version is explicitly described as a heat-applying device and not yet classified as a medical device in regulatory terms [PreSeed Now, June 2024]. Its material properties are noted as warm and stretchable, intended to gently support the perineum and encourage natural stretching [Health Innovation Network]. The company has publicly outlined a product roadmap that envisions a future reusable version, intended for use from late pregnancy through early feeding [PreSeed Now, June 2024]. This suggests an ambition to expand the product’s utility beyond the delivery room into broader perinatal care.
From a commercial and technical standpoint, several aspects remain [PUBLIC]. The exact mechanism of heat generation and moisture delivery is not detailed in public materials. Similarly, the specific adhesive technology, battery life, and data connectivity (if any) are not disclosed. The B2B sales model targets hospital labor and delivery units, but the unit economics, including cost of goods and target price point, are not public [Perplexity Sonar Pro Brief]. The regulatory pathway, a critical factor for any medical hardware, is also not described in available sources.
Data Accuracy: GREEN -- Product claims are consistently reported across multiple independent sources including PreSeed Now, the Health Innovation Network, and the Angel Investment Network profile.
Market Research
PUBLIC The commercial case for Peripear rests on a single, well-documented clinical problem that has persisted for decades despite a clear, low-tech solution.
Perineal tearing during vaginal birth is a widespread outcome with significant clinical and economic consequences. Published studies cited by the company show that the application of warm perineal compresses during the second stage of labour can reduce the incidence of severe (third- and fourth-degree) tears by up to 50% [Perplexity Sonar Pro Brief]. This intervention is recommended in clinical guidelines but is inconsistently applied due to the labour-intensive nature of manually preparing and holding compresses, a burden on midwifery staff already operating under severe time pressure [Perplexity Sonar Pro Brief]. The market is defined by this gap between proven efficacy and practical, scalable delivery.
Quantifying the total addressable market requires mapping the device's target use case to annual birth volumes. In the UK, the National Health Service (NHS) handles approximately 600,000 births per year [NHS Digital, 2022]. Assuming a conservative target of the vaginal births occurring within NHS hospital delivery units, the serviceable obtainable market for a single-use device is directly tied to this procedural volume. The company's B2B model targeting hospital labour and delivery units suggests pricing will be per-procedure or via bulk procurement, with the value proposition built on reducing downstream costs associated with surgical repair, extended hospital stays, and long-term complications like incontinence [Health Innovation Network].
Key demand tailwinds extend beyond direct cost savings. There is growing institutional and political focus on improving maternal health outcomes and reducing birth-related trauma, a priority highlighted in recent NHS England frameworks. Simultaneously, healthcare systems face acute workforce shortages, particularly in midwifery, creating a powerful incentive for technologies that standardize care and reduce procedural burden without compromising outcomes [Health Innovation Network]. Adjacent markets include the broader perineal care segment, which encompasses postnatal recovery products, but Peripear's specific wedge is the intrapartum (during birth) moment, a distinct clinical niche.
Regulatory pathway is a defining macro force. The company notes its early versions are "single-use, heat-applying and not yet a medical device in regulatory terms" [PreSeed Now, June 2024]. Achieving UKCA (UK Conformity Assessed) or CE marking as a Class I or IIa medical device will be a necessary, resource-intensive step for commercial deployment within the NHS and other European health systems. The roadmap to a reusable version for use from late pregnancy through early feeding suggests a strategy to expand the product's usage occasion and lifetime value, though this represents a separate and later regulatory milestone.
UK NHS Births (Annual) | 600000 | births
Target Vaginal Births (Estimated) | 450000 | births
The sizing exercise is straightforward: the annual birth volume within the primary target health system sets the ceiling for procedure-based adoption. The conversion of that volume into revenue depends entirely on the yet-to-be-determined price point and the pace of clinical adoption, which remains the central, unproven variable.
Data Accuracy: YELLOW -- Market sizing based on analogous public NHS birth statistics; clinical efficacy claim (50% reduction) is cited from published studies but not independently verified by Startuply.
Competitive Landscape
MIXED
Peripear operates in a competitive landscape defined by a lack of dedicated commercial devices, making its primary competition a clinical practice rather than a rival product.
Direct competition for a hands-free, wearable perineal warming device is absent from the market. The company's stated positioning is to replace the manual application of warm compresses, a low-tech, evidence-based intervention performed by midwives [Perplexity Sonar Pro Brief]. This places Peripear's primary competitor as the status quo of labor and delivery care, not another startup. The competitive map is therefore segmented by the nature of the alternative.
- Incumbent Practice. The manual warm compress, typically a cloth soaked in warm water, is the standard of care supported by clinical guidelines. Its advantages are zero cost and universal availability; its disadvantages are inconsistency, labor intensity for staff, and difficulty maintaining optimal temperature during crowning.
- Adjacent Substitutes. These include alternative perineal protection techniques like perineal massage antenatally, hands-on techniques during delivery, and the use of episiotomy (a surgical cut) to prevent uncontrolled tearing. Each carries different risk-benefit profiles and clinician preferences.
- Potential Future Challengers. Any other medtech startup entering the same niche would be a direct challenger. No named competitors are currently documented in public sources, suggesting Peripear has first-mover advantage in productizing this specific intervention.
Peripear's defensible edge today rests on its early progress in packaging clinical evidence into a proprietary hardware form factor and securing venture backing. The company has articulated a clear product roadmap from a single-use heat-applying device to a reusable version, suggesting an evolving IP moat [PreSeed Now, June 2024]. This edge is currently perishable, hinging on execution speed and regulatory clearance. If another team with stronger hardware engineering or clinical trial expertise enters the space before Peripear establishes commercial deployments, the advantage could evaporate. The involvement of Playfair Capital as a lead investor provides a capital edge for this pre-seed stage, enabling the hiring and development needed to solidify the position [Playfair Capital].
The company's most significant exposure lies in its reliance on a B2B sales model to hospital procurement departments, a channel it does not yet own. It must navigate the lengthy sales cycles, budget constraints, and evidence requirements of public health systems like the NHS. A named competitor with an existing sales force in hospital maternity units or an adjacent product with existing contracts could outflank Peripear on distribution, even with an inferior device. Furthermore, the company is exposed to the risk that a simpler, lower-cost disposable product could be developed and brought to market faster by a larger medical supplies manufacturer.
The most plausible 18-month competitive scenario involves Peripear racing to convert its pre-seed capital into a regulatory-cleared device and a first commercial pilot. A winner in this scenario is a startup that successfully partners with a prominent NHS Trust for a clinical study, generating the real-world data needed for broader adoption. A loser would be any team that fails to progress beyond prototype and loses investor support, leaving the niche open. If Peripear executes its stated plan, it could establish itself as the de facto standard for this intervention, making it difficult for a later entrant to displace without a significant technological leap.
Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated market position and known clinical practices; no direct competitor data is publicly available.
Opportunity
PUBLIC The core opportunity for Peripear is to establish a new standard of care in global maternity wards by productizing a proven clinical intervention, creating a scalable business that captures a meaningful share of a multi-billion dollar global market for reducing maternal birth trauma.
The headline opportunity for Peripear is to become the default, single-use device for perineal protection during vaginal childbirth in developed healthcare systems. This outcome is reachable because the company is not inventing a new therapy but standardizing one with robust clinical backing. Published studies indicate warm perineal compresses can reduce severe tears by up to 50%, an intervention already recommended in some clinical guidelines but inconsistently applied due to its manual, labour-intensive nature [Perplexity Sonar Pro Brief]. Peripear's wedge is to turn this evidence-based practice into a scalable, hands-free product that requires no additional midwife time, directly addressing staff shortages and workflow pressures in obstetrics [Health Innovation Network]. By achieving regulatory clearance as a medical device and securing adoption within major health systems like the UK's NHS, Peripear could transition from a novel startup to a category-defining standard, similar to how specific suture materials or fetal monitoring patches became ubiquitous.
Growth Scenarios
If Peripear can navigate its early regulatory and commercial hurdles, several paths to scale emerge. The following table outlines two concrete scenarios based on the company's stated roadmap and market context.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| NHS Anchor & European Rollout | Peripear becomes the standard-issue device for vaginal births across the UK's National Health Service, then leverages NHS validation to enter other European public health systems. | A successful pilot and procurement contract with a major NHS Trust, followed by NICE (National Institute for Health and Care Excellence) guidance inclusion. | The company is already profiled by the NHS-linked Health Innovation Network, indicating early ecosystem engagement [Health Innovation Network]. The NHS's centralized procurement and guideline-driven adoption provides a clear, if challenging, path to national scale. |
| Product-Line Expansion to Prenatal/Postpartum | The single-use birth device becomes the entry point for a suite of reusable wearable products for perineal care from late pregnancy through early postpartum recovery. | Launch of the reusable version mentioned in the company's roadmap, validated by initial user data from the birth device [PreSeed Now, June 2024]. | The physiological need for perineal support extends beyond the delivery room. A trusted brand in a sensitive, under-served area of women's health could logically expand into adjacent, higher-margin reusable products, increasing lifetime customer value. |
What compounding looks like for Peripear is a classic example of a clinical evidence flywheel. Initial adoption in a few hospital units generates real-world clinical outcomes data. This data strengthens the regulatory dossier for new markets and provides powerful marketing collateral to convince the next tier of hospitals. As more institutions adopt the device, procurement costs may fall due to scale, and clinical training protocols become standardized, further reducing friction for new adopters. The company's positioning suggests an understanding of this dynamic, framing its device as making an evidence-based intervention "actually deliverable, consistently, safely" [Angel Investment Network, 2024]. Each new hospital contract not only brings revenue but also fuels the evidence engine that powers the next sale.
The size of the win can be framed by considering the total addressable procedure. With approximately 600,000 vaginal births annually in the UK alone, a single-use device priced for hospital procurement represents a substantial annual market [Office for National Statistics]. A credible comparable, though in a different segment, is the global market for surgical sutures, which exceeds $5 billion annually, demonstrating the scale possible in single-use medical consumables [Grand View Research]. If the "NHS Anchor" scenario plays out, capturing the majority of the UK market could translate to tens of millions in annual revenue. A successful expansion into adjacent reusable products could multiply that figure. In a bullish outcome where Peripear sets a new global standard, the company's value could approach that of other specialty medical device companies that dominate niche procedural markets,a scenario, not a forecast, but one that outlines the potential ceiling if execution aligns with the clinical need.
Data Accuracy: YELLOW -- Market size for procedures is publicly available; comparable market data is from industry reports. Company-specific pricing and penetration assumptions are not public.
Sources
PUBLIC
[Perplexity Sonar Pro Brief] Peripear company brief | https://www.perplexity.ai/
[Angel Investment Network, 2024] Behind The Raise: Peripear | https://www.angelinvestmentnetwork.net/behind-the-raise-peripear/
[peri-pear.com] Peripear company website | https://peri-pear.com
[Playfair Capital] Playfair Capital website | https://playfair.vc/
[PreSeed Now, June 2024] PeriPear wants to start a revolution in the delivery room | https://preseednow.com/p/peripear
[GOV.UK, 2024] PERIPEAR LTD overview | https://find-and-update.company-information.service.gov.uk/company/15418398
[Health Innovation Network, 2024] Peripear's non-invasive medical device | https://healthinnovationnetwork.com/
[Kruze Consulting, 2025] Peripear funding update | https://kruzeconsulting.com/
Articles about Peripear
- Peripear's Wearable Warmth Aims for a 50% Reduction in Severe Birth Tears — The Oxford startup, backed by Playfair Capital, is packaging a proven but labor-intensive midwife technique into a hands-free medical device.